{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:55:25Z","timestamp":1771674925723,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Veloce Biopharma"},{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"Dermatology Foundation Career Development Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10637-019-00825-0","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T02:04:03Z","timestamp":1561514643000},"page":"1247-1256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia"],"prefix":"10.1007","volume":"37","author":[{"given":"Kara D.","family":"Capriotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Anadkat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Barone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwaseun","family":"Kukoyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shari","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"issue":"3","key":"825_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/1078155212461289","volume":"19","author":"SL Lee","year":"2013","unstructured":"Lee SL, Tan BS, Chan LC (2013) Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. J Oncol Pharm Pract 19(3):273\u2013278","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"825_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2230.2008.02928.x","volume":"34","author":"D Rigopoulos","year":"2009","unstructured":"Rigopoulos D, Gregoriou S, Belyayeva Y et al (2009) Acute paronychia caused by lapatinib therapy. Clin Exp Dermatol 34(1):94\u201395","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"825_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000073100","volume":"207","author":"Teruki Dainichi","year":"2003","unstructured":"Dainichi T, Tanaka M, Tsuruta N et al (2003) Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology (3):324\u2013325","journal-title":"Dermatology"},{"issue":"4","key":"825_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1067\/mjd.2002.124621","volume":"47","author":"KW Boucher","year":"2002","unstructured":"Boucher KW, Davidson K, Mirakhur B et al (2002) Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 47(4):632\u2013633","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"825_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1346-8138.2003.tb00387.x","volume":"30","author":"J Nakano","year":"2003","unstructured":"Nakano J, Nakamura M (2003) Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Dermatol 30(3):261\u2013262","journal-title":"J Dermatol"},{"issue":"3","key":"825_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1078155208100450","volume":"15","author":"P Gilbar","year":"2009","unstructured":"Gilbar P, Hain A, Peereboom VM (2009) Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract 15(3):143\u2013155","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"825_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1001\/jamadermatol.2017.4120","volume":"154","author":"X Cubir\u00f3","year":"2018","unstructured":"Cubir\u00f3 X, Planas-Ciudad S, Garcia-Murett MP, Puig L (2018) Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine. JAMA Dermatol 154(1):99\u2013100","journal-title":"JAMA Dermatol"},{"issue":"7","key":"825_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s00105-013-2733-8","volume":"65","author":"R Gutzmer","year":"2014","unstructured":"Gutzmer R, Hassel JC, K\u00e4hler KC et al (2014) Cutaneous adverse events of anti-tumor therapy with BRAF and MEK inhibitors. Hautarzt 65(7):582\u2013589","journal-title":"Hautarzt"},{"issue":"3","key":"825_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaad.2011.10.009","volume":"67","author":"BC Garden","year":"2012","unstructured":"Garden BC, Wu S, Lacouture ME (2012) The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 67(3):500\u2013508","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"825_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/bjd.13743","volume":"17","author":"K Capriotti","year":"2015","unstructured":"Capriotti K, Capriotti J, Lessen S, al e (2015) The risk of nail changes with taxane chemotherapy: a Systematic review of the literature and meta-analysis. Br J Dermatol 17(3):842\u2013845","journal-title":"Br J Dermatol"},{"key":"825_CR11","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","volume":"29","author":"Y Balagula","year":"2011","unstructured":"Balagula Y, Barth Huston K, Busam KJ et al (2011) Dermatologic adverse events associated with MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY 142886). Invest New Drugs 29:1114\u20131121","journal-title":"Invest New Drugs"},{"key":"825_CR12","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-09-1766","volume":"16","author":"K Schad","year":"2010","unstructured":"Schad K, Baumann Conzett K, Zipser MC et al (2010) Mitogen-activated protein\/extracellular signal regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 16:1058\u20131064","journal-title":"Clin Cancer Res"},{"key":"825_CR13","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","volume":"22","author":"E Raymond","year":"2004","unstructured":"Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmocokinetics of escalated weekly intraveneous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336\u20132347","journal-title":"J Clin Oncol"},{"key":"825_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/sj.ki.5002116","volume":"71","author":"DL Raju","year":"2007","unstructured":"Raju DL, Bitzan M (2007) Sirolimus-associated chronic pyogenic granuloma periungual infection. Kidney Int 71:476","journal-title":"Kidney Int"},{"key":"825_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","volume":"14","author":"AC Rosen","year":"2013","unstructured":"Rosen AC, Case EC, Dusza SW et al (2013) Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 14:327\u2013333","journal-title":"Am J Clin Dermatol"},{"key":"825_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/annonc\/mdg050","volume":"14","author":"AM Minisini","year":"2002","unstructured":"Minisini AM, Tosti A, Sobrero AF et al (2002) Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 14:333\u2013337","journal-title":"Ann Oncol"},{"issue":"4","key":"825_CR17","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","volume":"16","author":"C Robert","year":"2015","unstructured":"Robert C, Sibaud V, Mateus C et al (2015) Nail toxicities induced by systemic chemotherapy treatments. Lancet Oncol 16(4):e181\u2013e190","journal-title":"Lancet Oncol"},{"key":"825_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.clindermatol.2013.06.013","volume":"5","author":"BM Piracccine","year":"2013","unstructured":"Piracccine BM, Alessandrini A (2013) Drug-related nail disease. Clin Dermatol 5:618\u2013626","journal-title":"Clin Dermatol"},{"issue":"9","key":"825_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/CMAR.S139301","volume":"26","author":"K Capriotti","year":"2017","unstructured":"Capriotti K, Capriotti J, Pelletier J, Stewart K (2017) Chemotherapy-associated paronychia treated with 2% povidone-iodine: A series of cases. Cancer Manag Res 26(9):225\u2013228","journal-title":"Cancer Manag Res"},{"key":"825_CR20","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events and Common Toxicity Criteria [v4.0]. 15-12-2010."},{"key":"825_CR21","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","volume":"16","author":"V Sibaud","year":"2011","unstructured":"Sibaud V, Dalenc F, Chevreau C et al (2011) HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand\u2013Foot Syndrome. Oncologist 16:1469\u20131478","journal-title":"Oncologist"},{"issue":"1","key":"825_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1067\/mjd.2002.122191","volume":"47","author":"A Tosti","year":"2002","unstructured":"Tosti A, Piraccini BM, Ghetti E, Colombo MD (2002) Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study. Jour Am Acad Dermatol 47(1):73\u201376","journal-title":"Jour Am Acad Dermatol"},{"issue":"1","key":"825_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1046\/j.1468-3083.2001.00177-6.x","volume":"15","author":"U Wollina","year":"2001","unstructured":"Wollina U (2001) Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid. J Eur Acad Dermatol Venereol 15(1):82\u201384","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"825_CR24","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/j.1365-2133.2008.08988.x","volume":"160","author":"D Rigopoulos","year":"2009","unstructured":"Rigopoulos D, Gregoriou S, Belyayeva E et al (2009) Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. Br Jour Dermatol 160(4):858\u2013860","journal-title":"Br Jour Dermatol"},{"issue":"6","key":"825_CR25","first-page":"397","volume":"58","author":"CR Daniel","year":"1996","unstructured":"Daniel CR, Daniel MP, Daniel CM et al (1996) Chronic paronychia and onycholysis: a thirteen-Year experience. Cutis 58(6):397\u2013501","journal-title":"Cutis"},{"issue":"4","key":"825_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1128\/CMR.10.4.597","volume":"10","author":"WA Rutala","year":"1997","unstructured":"Rutala WA, Weber DJ (1997) Uses of inorganic hypochlorite (bleach) in health-care facilities. Clin Microbiol Rev 10(4):597\u2013610","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"825_CR27","first-page":"824","volume":"51","author":"D Rosenbaum","year":"2002","unstructured":"Rosenbaum D, Merenstein D, Meyer F (2002) Topical steroids more effective than antifungals for chronic paronychia. J Fam Pract 51(10):824","journal-title":"J Fam Pract"},{"issue":"1","key":"825_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2133.2005.07010.x","volume":"154","author":"KY Suh","year":"2006","unstructured":"Suh KY, Kindler HL, Medenica M, Lacouture M (2006) Doxycycline for the treatment of Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br Jourm Dermatol 154(1):191\u2013192","journal-title":"Br Jourm Dermatol"},{"issue":"3","key":"825_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1053\/jhsu.2003.50092","volume":"28","author":"HM Quitkin","year":"2003","unstructured":"Quitkin HM, Rosenwasser MP, Strauch RJ (2003) The efficacy of silver nitrate cauterization for pyogenic granuloma of the hand. Jour Hand Surg Am 28(3):435\u2013438","journal-title":"Jour Hand Surg Am"},{"issue":"4","key":"825_CR30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2133.2005.06923.x","volume":"154","author":"SZ Ghodsi","year":"2006","unstructured":"Ghodsi SZ, Raziei M, Taheri A (2006) et ak. Comparison of cryotherapy and curettage for the treatment of pyogenic granuloma: a randomized trial. Br Jour Dermatol 154(4):671\u2013675","journal-title":"Br Jour Dermatol"},{"issue":"12","key":"825_CR31","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1001\/archdermatol.2012.3022","volume":"148","author":"SH Kwon","year":"2012","unstructured":"Kwon SH, Choi JW, Hong JS et al (2012) Gefitinib-induced paronychia: response to autologous platelet-rich plasma. Arch Dermatol 148(12):1399\u20131402","journal-title":"Arch Dermatol"},{"issue":"3","key":"825_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/ccr3.1399","volume":"6","author":"Y Hosono","year":"2018","unstructured":"Hosono Y, Uenami T, Yano Y, Mori M (2018) Febrile neutropenia with bacterial paronychia. Clin Case Rep 6(3):543\u2013544","journal-title":"Clin Case Rep"},{"issue":"4","key":"825_CR33","first-page":"191","volume":"85","author":"GP Bourgeois","year":"2010","unstructured":"Bourgeois GP, Cafardi JA, Sellheyer K, Andea AA (2010) Disseminated Fusarium infection originating from paronychia in a neutropenic patient: a case report and review of the literature. Cutis 85(4):191\u2013194","journal-title":"Cutis"},{"issue":"4","key":"825_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000490177","volume":"95","author":"K Masago","year":"2018","unstructured":"Masago K, Irie K, Fujita S et al (2018) Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Oncology 95(4):251\u2013256","journal-title":"Oncology"},{"key":"825_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00002018-199921030-00004","volume":"21","author":"BM Piraccini","year":"1999","unstructured":"Piraccini BM, Tosti A (1999) Drug-induced nail disorders: incidence, management and prognosis. Drug Saf 21:187\u2013201","journal-title":"Drug Saf"},{"key":"825_CR36","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201\u20131208","journal-title":"J Clin Oncol"},{"issue":"1","key":"825_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/jdv.15121","volume":"33","author":"P.-H. Ho","year":"2018","unstructured":"Ho PH, Lin IC, Yang X et al (2018 Jun 12) Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.15121","journal-title":"Journal of the European Academy of Dermatology and Venereology"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00825-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00825-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00825-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:40:14Z","timestamp":1678560014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00825-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["825"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00825-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"assertion":[{"value":"16 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K. Capriotti owns equity and is an employee of Veloce BioPharma. M. Anadkat has received honoraria for consulting and\/or speaking engagements in the past from Adgero, Astra Zeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Biogen, Eli Lilly, Genentech, ImClone, Therakos, Xoma, and Eisai and has also served as a Principal Investigator for Biogen, Veloce BioPharma, Xoma, Hana Biosciences, and InflamRx. J. Choi declares that she has no conflict of interest. B. Kaffenberger is an Investigator for Biogen, Celgene, Eli Lilly Co, and Veloce BioPharma. B. McLellan has served as an investigator for Veloce BioPharma. S. Barone owns equity and is an employee of Veloce BioPharma. All other authors have declared no relevant conflicts of interest. O. Kukoyi declares that he has no conflict of interest. S. Goldfarb declares that she has no conflict of interest. M. Lacouture has a consultant\/speaking role with Legacy Healthcare Services, Adgero Bio Pharmaceuticals, Amryt Pharmaceuticals, Celldex Therapeutics, Debiopharm, Galderma Research and Development, Johnson and Johnson, Novocure Inc., Lindi, Merck Sharp and Dohme Corporation, Helsinn Healthcare SA, Janssen Research & Development LLC, Menlo Therapeutics, Novartis Pharmaceuticals Corporation, F. Hoffmann-La Roche AG, AbbVie Inc., Boehringer Ingelheim Pharma Gmbh & Co. KG, Allergan Inc., Amgen Inc., E.R. Squibb & Sons LLC, EMD Serono Inc., AstraZeneca Pharmaceuticals LP, Genentech Inc., Leo Pharma Inc., Seattle Genetics, Bayer, Manner SAS, Lutris, Pierre Fabre, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Teva Mexico, Parexel, OnQuality Pharmaceuticals Ltd., Oncoderm, Apricity, Novartis, and Our Brain Bank. Dr. Lacouture also receives research funding from Berg, Bristol-Myers Squibb, Lutris, Paxman, Novocure, US Biotest, and Veloce BioPharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}